The software turns standard eye images into personalized systemic risk insights, helping care teams flag patients at elevated risk for cardiovascular, kidney, and neurological conditions earlier.
Charlotte, North Carolina —
PRiSM AI has filed a U.S. patent application for a software platform that analyzes routine retinal images to stratify a patient's systemic health risk, and now holds Patent Pending status. The platform helps clinicians spot patients who look similar on a standard eye exam but carry very different risk for heart, kidney, and neurological disease.
The retina gives clinicians a direct, noninvasive view of the body's blood vessels and nerve tissue. Yet most eye-clinic workflows stop at diagnosing eye disease and assigning a broad retinopathy grade. PRiSM AI's platform goes further. It brings together several kinds of retinal images from standard clinical cameras, aligns them into a single structured map of the eye, and pulls out interpretable measures of vessels, blood flow, leakage, and tissue structure. It then combines those signals with a patient's medical history, medications, and lifestyle to produce a personalized, wellness-oriented view of systemic risk. The outputs support care decisions and are not a diagnosis.
Because it works with images clinics already capture, the platform fits existing workflows and needs no new hardware. It flags high-risk patients earlier, tracks whether a person's risk is rising or falling over time, and gives care teams population-level views to prioritize outreach. Interest in applying AI to eye imaging is climbing fast. Analysts valued the AI in ophthalmology market at about $291.5 million in 2025 and project a 38.3% annual growth rate through 2035 (Market.us, 2025). PRiSM AI's work sits at the intersection of that market and the far larger challenge of catching systemic disease before it becomes an emergency.
Patent Pending status marks an important step in protecting the platform's core methods. It also signals PRiSM AI's commitment to building a defensible technology position as it works with clinical and research partners.
"Doctors already look at the retina every day. We built PRiSM AI to help them see more in those same images. Not just the health of the eye, but early signals about the heart, kidneys, and brain. Filing this patent application protects the core of how we do that, and it lets us move faster with the clinics and partners who want to catch risk earlier. This is the foundation we will build on."
"PRiSM AI shows what disciplined IP strategy looks like. They took real engineering in retinal imaging and turned it into a portfolio that protects the core invention and opens new markets in systemic health. That is how innovation becomes a durable business asset. At ipCG, we help companies capture the full value of what they invent, and it has been a pleasure to support PRiSM AI as they extend their lead."
PRiSM AI develops software that turns routine retinal imaging into insight about a patient's whole-body health. Its platform helps clinicians and care teams identify systemic risk earlier, personalize wellness interventions, and monitor risk over time using images that clinics already capture. Learn more at prismaisolutions.org.
ipCapital Group (ipCG), founded in 1998 and headquartered in Essex, Vermont, is recognized as the world's first IP strategy consulting firm. ipCG helps companies capture, protect, and monetize their innovation through IP strategy, invention capture, patent portfolio development, IP analytics, valuation, and trade secret programs. Learn more at ipcg.com.
PRiSM AI has filed one or more U.S. patent applications covering its retinal systemic risk platform and holds Patent Pending status. Additional elements, including proprietary methods and implementation details, are maintained as trade secrets and are not disclosed in this release. This release contains forward-looking statements that involve risks and uncertainties, and actual results may differ.
###